Chen et al. found that in patients with metastatic melanoma on anti-PD-1 therapy [46], higher levels of baseline circulating exosomal PD-L1 pre-treatment were correlated with poorer clinical outcomes (P = 0.0018). This evidence concerns the gene CD274 and metastatic melanoma.